Atl i, acts as a sirt6 activator to alleviate hepatic steatosis in mice via suppression of nlrp3 inflammasome formation

HIGHLIGHTS

• who: Danli Kong and colleagues from the Department of Epidemiology and Medical Statistics, School of Public Health, Guangdong Medical University, Dongguan, China have published the research: ATL I, Acts as a SIRT6 Activator to Alleviate Hepatic Steatosis in Mice via Suppression of NLRP3 Inflammasome Formation, in the Journal: Pharmaceuticals 2022, 15, x FOR PEER REVIEW of /2022/
• what: The authors aim to investigate the underlying mechanisms and pharmacological interventions of SIRT6 on hepatic steatosis treatment. The authors first explored the underlying mechanism by which ATL I regulates hepatic inflammation. In the present study, the results . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.